IP Library Granted Patent US 12,233,099
Granted Patent B2
US 12,233,099 · App. 17/059,122 · Granted Feb 25, 2025

Composition for promoting myogenesis, containing processed ginseng extract

Inventors: Sun Kyu Park (Seongnam-si, KR); Jeom Yong Kim (Seongnam-si, KR); Young Hyo Yoo (Seongnam-si, KR); Min Jung Jang (Seongnam-si, KR); Chang Taek Oh (Seongnam-si, KR); Min Ju Lim (Seongnam-si, KR); Gwan Su Yi (Daejeon, KR); Yi Li (Daejeon, KR); Yoon Hyeok Lee (Seoul, KR); Jae Cheal Yoo (Jinju-si, KR)
Assignee: GREEN CROSS WELLBEING CORPORATION
A61K36/258A23L33/105A23L33/40A61K9/0056A61K31/704A61P21/00A23V2002/00A61K2236/19A61K2236/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,099
App. No.
17/059,122
Granted
Feb 25, 2025
Kind
B2
Abstract

The present invention relates to a composition for promoting myogenesis, containing, as an active ingredient, a processed ginseng extract in which a trace amount of a ginsenoside ingredient is increased. It has been ascertained that the processed ginseng extract promotes the differentiation of myoblasts into muscle and inhibits muscle atrophy caused by myostatin, which is a myogenesis inhibitory factor, and thus it is expected that a composition for preventing or treating muscle disorder-related diseases, having excellent effects, can be developed.

Claims (15)

1. A method for treating a muscle-atrophy-related disease in a mammal in need thereof, comprising administering to the mammal an extract of processed ginseng, wherein the muscle atrophy-related disease is selected from the group consisting of muscular atrophy, myopathy, muscular injury, muscular dystrophy, myasthenia, myoneural conductive disease, dermatomyositis, diabetic amyotrophy, nerve injury, amyotrophic lateral sclerosis (ALS), cachexia, and degenerative muscle diseases,

wherein the extract of processed ginseng inhibits myoatrophy caused by myostatin,

wherein the extract of processed ginseng is prepared by:

(a) seeding Aspergillus niger strain on a medium containing a ginseng powder and bran;

(b) culturing the strain in step (a);

(c) purifying the culture in step (b) through an ultrafiltration membrane;

(d) separating an enzyme from the purification product in step (c);

(e) adding the enzyme in step (d) to a ginseng powder, a red ginseng powder, a ginseng extract, or a red ginseng extract;

(f) fermenting the product after addition in step (e);

(g) separating the fermentation product in step (f);

(h) concentrating a supernatant in step (g);

(i) reacting the concentration product in step (h) with at least one organic acid selected from the group consisting of acetic acid, lactic acid, citric acid, malic acid, and tartaric acid; and

(j) neutralizing, filtering, purifying, concentrating, and drying the reaction product in step (i), and

wherein the extract of processed ginseng contains ginsenosides Rh2 and Rg3 each in 0.5-30 wt %.

2. The method of claim 1 , wherein the cachexia is caused by at least one selected from the group consisting of acquired immune deficiency syndrome (AIDS), celiac disease, multiple sclerosis, rheumatoid arthritis, chronic heart failure, congestive heart failure, uremia, tuberculosis, Crohn's disease, untreated or severe type 1 diabetes, anorexia nervosa, and hormone deficiency.

Assignments (2)
CHANGE OF ADDRESS Recorded Dec 7, 2021
From: GREEN CROSS WELLBEING CORPORATION
To: GREEN CROSS WELLBEING CORPORATION
Reel/Frame 058357/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2020
From: PARK, SUN KYU; KIM, JEOM YONG; YOO, YOUNG HYO; JANG, MIN JUNG; OH, CHANG TAEK; LIM, MIN JU; YI, GWAN SU; LI, YI; LEE, YOON HYEOK; YOO, JAE CHEAL
To: GREEN CROSS WELLBEING CORPORATION
Reel/Frame 054472/0531 →
Priority Claims (1)
KR 10-2018-0059749 · May 25, 2018 · national
Continuity (1)
Related Publication 20210205387A1 · Jul 8, 2021
References Cited (22)
US 9512453B2 · Yoo et al. · 2016 [cited by applicant]
US 20160213723A1 · Yoo et al. · 2016 [cited by applicant]
US 20170260275A1 · Kortebein et al. · 2017 [cited by applicant]
CN 103724391A · 2014 [cited by examiner]
JP 2008179620A · 2008 [cited by applicant]
JP 2017149749A · 2017 [cited by applicant]
KR 100992800B1 · 2010 [cited by applicant]
KR 101595426B1 · 2016 [cited by applicant]
KR 20170001037A · 2017 [cited by examiner]
KR 1020170058035A · 2017 [cited by applicant]
KR 101771486B1 · 2017 [cited by applicant]
KR 20170094292A · 2017 [cited by applicant]
KR 101966117B1 · 2019 [cited by applicant]
Meng Sijin, Advances in Molecular Biology of Skeletal Muscle Cells, pp. 177-178, Wuhan University of Technology Press, Dec. 2010. [cited by applicant]
Extended European Search Report issued for European Patent Application No. 19 807 637.4 on Jan. 7, 2022, 10 pages. [cited by applicant]
Go Ga-Yeon et al., Ginsenoside Rg1 from Panax ginseng enhances, myoblast differentiation and myotube growth, Journal of Ginseng Research. 2017;41(4): 608-614. [cited by applicant]
International Search Report issued for International Application No. PCT/KR2019/006265 on Sep. 3, 2019, 4 pages. [cited by applicant]
Lee SY, et al., Black ginseng activates Akt signaling, thereby enhancing myoblast differentiation and myotube growth, J Ginseng Res., 2018;42(1):116-121. [cited by applicant]
Chen CF, et al., Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium, Acta Pharmacol Sin., 2008;29(9):1103-1108. [cited by applicant]
Kim HS, et al., Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells, Arch Pharm Res., 2004;27(4):429-435. [cited by applicant]
Li F, et al., Ginsenoside Rg1 prevents starvation-induced muscle protein degradation via regulation of AKT/mTOR/FoxO signaling in C2C12 myotubes., Exp. Ther. Med., 2017;14(2):1241-1247. [cited by applicant]
Lobina C, et al. Protective effect of Panax ginseng in cisplatininduced cachexia in rats, Future Oncol., 2014;10(7):1203-1214. [cited by applicant]